These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9443356)

  • 21. The regulation of forebrain dopamine transmission: relevance to the pathophysiology and psychopathology of schizophrenia.
    Moore H; West AR; Grace AA
    Biol Psychiatry; 1999 Jul; 46(1):40-55. PubMed ID: 10394473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dopamine D2 receptor binding in drug-naïve patients with schizophrenia examined with raclopride-C11 and positron emission tomography.
    Talvik M; Nordström AL; Okubo Y; Olsson H; Borg J; Halldin C; Farde L
    Psychiatry Res; 2006 Dec; 148(2-3):165-73. PubMed ID: 17095199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intramembrane interactions between neurotensin receptors and dopamine D2 receptors as a major mechanism for the neuroleptic-like action of neurotensin.
    Fuxe K; Von Euler G; Agnati LF; Merlo Pich E; O'Connor WT; Tanganelli S; Li XM; Tinner B; Cintra A; Carani C
    Ann N Y Acad Sci; 1992; 668():186-204. PubMed ID: 1361113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GABA-ergic neurons and the neurobiology of schizophrenia and other psychoses.
    Keverne EB
    Brain Res Bull; 1999 Mar; 48(5):467-73. PubMed ID: 10372507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.
    Sharma RP; Janicak PG; Bissette G; Nemeroff CB
    Am J Psychiatry; 1997 Jul; 154(7):1019-21. PubMed ID: 9210757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Basal ganglia pathology in schizophrenia: dopamine connections and anomalies.
    Perez-Costas E; Melendez-Ferro M; Roberts RC
    J Neurochem; 2010 Apr; 113(2):287-302. PubMed ID: 20089137
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study.
    Pilowsky LS; Costa DC; Ell PJ; Murray RM; Verhoeff NP; Kerwin RW
    Psychol Med; 1993 Aug; 23(3):791-7. PubMed ID: 7901865
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-Iodobenzamide in chronic schizophrenia.
    Volk S; Maul FD; Hör G; Schreiner M; Weppner M; Holzmann T; Pflug B
    Psychiatry Res; 1994 Jun; 55(2):111-8. PubMed ID: 10711799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia.
    Meltzer HY; Massey BW; Horiguchi M
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1572-86. PubMed ID: 22283753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Deficient inhibitory cortical networks in antipsychotic-naive subjects at risk of developing first-episode psychosis and first-episode schizophrenia patients: a cross-sectional study.
    Hasan A; Wobrock T; Grefkes C; Labusga M; Levold K; Schneider-Axmann T; Falkai P; Müller H; Klosterkötter J; Bechdolf A
    Biol Psychiatry; 2012 Nov; 72(9):744-51. PubMed ID: 22502988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modeling "psychosis" in vitro by inducing disordered neuronal network activity in cortical brain slices.
    Aghajanian GK
    Psychopharmacology (Berl); 2009 Nov; 206(4):575-85. PubMed ID: 19241062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: III. Retinoids.
    Citver AS; Shields AM; Ciaccia LM; Schulingkamp RJ; Raffa RB
    J Clin Pharm Ther; 2002 Jun; 27(3):161-8. PubMed ID: 12081629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis.
    Crippa JA; Hallak JE; Abílio VC; de Lacerda AL; Zuardi AW
    CNS Neurol Disord Drug Targets; 2015; 14(8):970-8. PubMed ID: 26350340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Concepts in Dopamine D
    Urs NM; Peterson SM; Caron MG
    Biol Psychiatry; 2017 Jan; 81(1):78-85. PubMed ID: 27832841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET.
    Gray NS; Pilowsky LS; Gray JA; Kerwin RW
    Schizophr Res; 1995 Sep; 17(1):95-107. PubMed ID: 8541255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deletion of dopamine D
    Tomasella E; Bechelli L; Ogando MB; Mininni C; Di Guilmi MN; De Fino F; Zanutto S; Elgoyhen AB; Marin-Burgin A; Gelman DM
    Proc Natl Acad Sci U S A; 2018 Mar; 115(13):3476-3481. PubMed ID: 29531031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Blocking D2/D3 Receptors on Mismatch Negativity and P3a Amplitude of Initially Antipsychotic Naïve, First Episode Schizophrenia Patients.
    Düring S; Glenthøj BY; Oranje B
    Int J Neuropsychopharmacol; 2015 Oct; 19(3):pyv109. PubMed ID: 26453696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gamma band oscillations: a key to understanding schizophrenia symptoms and neural circuit abnormalities.
    McNally JM; McCarley RW
    Curr Opin Psychiatry; 2016 May; 29(3):202-10. PubMed ID: 26900672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2a/D2 receptor interaction in globus pallidus.
    Dayne Mayfield R; Larson G; Orona RA; Zahniser NR
    Synapse; 1996 Feb; 22(2):132-8. PubMed ID: 8787129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathophysiology of antipsychotic drug-induced movement disorders.
    Casey DE
    J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.